Home » Topics » BioWorld Science, Cancer

BioWorld Science, Cancer
RSS

Ideaya submits IND for phase I evaluation of MAT2A inhibitor IDE-397

Jan. 11, 2021

Dana-Farber Cancer Institute patents EGFR allosteric inhibitors

Jan. 11, 2021

CARs with switches

Jan. 11, 2021

Pfizer and CTxT Pty synthesize KAT inhibitors

Jan. 8, 2021

Chinese researchers presents new SERCAs for breast cancer

Jan. 8, 2021

Beijing Reciproca Pharmaceuticals patents new CDK inhibitors

Jan. 8, 2021

New ISR pathway inhibitors presented by Praxis Biotech

Jan. 7, 2021

JS Innopharm (Shanghai) identifies RET and/or VEGFR-2 inhibitors

Jan. 7, 2021

IHMT-TRK-284 shows efficacy in models of TRK kinase fusion or mutant-driven cancers

Jan. 7, 2021

The Vanderbilt University synthesizes new compounds for cancer

Jan. 7, 2021

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 13, 2026.
FENS 2026: Next-gen biologics take on brain disease
BioWorld
Whether by fine-tuning neurotransmitter signaling or silencing disease-associated genes, emerging biologic therapies are reshaping neuroscience drug development,...
Ionis, AZ shares down on unexpected Wainua flop in cardiomyopathy
BioWorld
News of the unexpected phase III failure of the gene silencing drug Wainua (eplontersen) in the treatment of transthyretin-mediated amyloid cardiomyopathy sent...
Neurovalens granted FDA approval for PTSD therapy for US veterans
BioWorld
Veterans in the U.S. suffering from post-traumatic stress disorder (PTSD) now have access to Neurovalens Ltd.’s Modius Spero, a wearable neuromodulation device,...
NRF2 activators reported in Vailima Peninsula patent
BioWorld Science
Vailima Peninsula Pty Ltd. has discovered new nuclear factor erythroid 2-related factor 2 (NFE2L2; NRF2) activators potentially useful for the treatment of...